| Oluyemisi Omolara Sokunbi-jones, | |
|
18 Endwell Ln, Willingboro, NJ 08046-2332 | |
| (908) 338-6015 | |
| Not Available |
| Full Name | Oluyemisi Omolara Sokunbi-jones |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 18 Endwell Ln, Willingboro, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356056279 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 863900 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Oluyemisi Omolara Sokunbi-jones, 18 Endwell Ln, Willingboro, NJ 08046-2332 Ph: (908) 338-6015 | Oluyemisi Omolara Sokunbi-jones, 18 Endwell Ln, Willingboro, NJ 08046-2332 Ph: (908) 338-6015 |
News Archive
New data released by the American Society of Plastic Surgeons reveals that Americans want to put their best face and body forward as their annual plastic surgery procedural statistics show a three percent growth in cosmetic procedures over the last year.
A collaboration between the Universities of Bristol, Cardiff and Swansea has been awarded £5 million by the UK Clinical Research Collaboration (UKCRC) to establish a Centre of Excellence for research into public health.
Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.
A vaccine for the novel coronavirus has been developed that is 91.27% effective. If public health officials present this information using the specific number, people are likely to think the vaccine is actually less effective than if it is presented as being 90% effective.
Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.
› Verified 8 days ago
Mr. Timothy Guito, CRNA Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 218a Sunset Rd, Willingboro, NJ 08046 Phone: 609-835-3069 Fax: 856-829-0580 | |
Ms. Linda Vasdias, CRNA Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 218a Sunset Rd, Willingboro, NJ 08046 Phone: 609-835-3069 Fax: 856-829-0580 | |
Naomi Boney-santiago, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 60 Ballad Ln, Willingboro, NJ 08046 Phone: 800-950-6066 | |
Jennifer Umek, APN Registered Nurse Medicare: Medicare Enrolled Practice Location: 200 Campbell Dr Ste 101, Willingboro, NJ 08046 Phone: 609-877-8777 | |
Mr. Barry Liimakka, CRNA Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 218a Sunset Rd, Willingboro, NJ 08046 Phone: 609-835-2900 Fax: 856-829-0580 | |
Charlise E Cole, CRNA Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 218a Sunset Rd, Willingboro, NJ 08046 Phone: 609-835-2901 |